Patents by Inventor Xiaozhao Wang

Xiaozhao Wang has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Substituted [1,2,4]triazolo[1,5-a]pyrazines as LSD1 inhibitors
    Patent number: 10968221
    Abstract: The present invention is directed to [1,2,4]triazolo[1,5-a]pyridine and [1,2,4]triazolo[1,5-a]pyrazine derivatives of Formula IIa, or a pharmaceutically acceptable salt thereof, which are LSD1 inhibitors useful in the treatment of diseases such as cancer.
    Type: Grant
    Filed: October 3, 2019
    Date of Patent: April 6, 2021
    Assignee: Incyte Corporation
    Inventors: Liangxing Wu, Xiaozhao Wang, Wenqing Yao, Colin Zhang
  • TRIAZOLOPYRIMIDINES AS A2A / A2B INHIBITORS
    Publication number: 20210061809
    Abstract: This application relates to compounds of Formula (I): or pharmaceutically acceptable salts or stereoisomers thereof, which modulate the activity of adenosine receptors, such as subtypes A2A and A2B receptors, and are useful in the treatment of diseases related to the activity of adenosine receptors including, for example, cancer, inflammatory diseases, cardiovascular diseases, and neurodegenerative diseases.
    Type: Application
    Filed: August 25, 2020
    Publication date: March 4, 2021
    Inventors: Heeoon Han, Le Zhao, Wenqing Yao, Xiaozhao Wang
  • CYCLOPROPYLAMINES AS LSD1 INHIBITORS
    Publication number: 20210032244
    Abstract: The present invention is directed to cyclopropylamine derivatives which are LSD1 inhibitors useful in the treatment of diseases such as cancer.
    Type: Application
    Filed: June 9, 2020
    Publication date: February 4, 2021
    Inventors: Liangxing Wu, Joel R. Courter, Chunhong He, Ding-Quan Qian, Bo Shen, Xiaozhao Wang, Wenqing Yao, Fenglei Zhang
  • Pyrrolotriazine compounds as TAM inhibitors
    Patent number: 10844069
    Abstract: This application relates to compounds of Formula I: or pharmaceutically acceptable salts thereof, which are inhibitors of TAM kinases which are useful for the treatment of disorders such as cancer.
    Type: Grant
    Filed: September 4, 2019
    Date of Patent: November 24, 2020
    Assignee: Incyte Corporation
    Inventors: Yun-Long Li, Xiaozhao Wang, Chunhong He
  • BICYCLIC HETEROCYCLES AS FGFR4 INHIBITORS
    Publication number: 20200306256
    Abstract: The present disclosure relates to bicyclic heterocycles, and pharmaceutical compositions of the same, that are inhibitors of the FGFR3 and/or FGFR4 enzyme and are useful in the treatment of FGFR-associated diseases.
    Type: Application
    Filed: March 12, 2020
    Publication date: October 1, 2020
    Inventors: Liang Lu, Bo Shen, Alexander Sokolsky, Xiaozhao Wang, Liangxing Wu, Wenqing Yao, Yingda Ye
  • PYRAZOLOPYRIDINES AND TRIAZOLOPYRIDINES AS A2A / A2B INHIBITORS
    Publication number: 20200270244
    Abstract: This application relates to compounds of Formula (I): or pharmaceutically acceptable salts thereof, which modulate the activity of adenosine receptors, such as subtypes A2A and A2B receptors, and are useful in the treatment of diseases related to the activity of adenosine receptors including, for example, cancer, inflammatory diseases, cardiovascular diseases, and neurodegenerative diseases.
    Type: Application
    Filed: January 28, 2020
    Publication date: August 27, 2020
    Inventors: Taisheng Huang, Xiaozhao Wang
  • Heterocyclic compounds and uses thereof
    Patent number: 10723705
    Abstract: The present disclosure relates to heterocyclic compounds, and pharmaceutical compositions of the same, that are modulators/inhibitors of HDACs, such as HDAC8 and are useful in the treatment of HDAC-associated diseases.
    Type: Grant
    Filed: August 12, 2016
    Date of Patent: July 28, 2020
    Assignee: Incyte Corporation
    Inventors: Jun Pan, Xiaozhao Wang, Joseph Barbosa, Wenqing Yao, Yingda Ye
  • PYRROLOPYRIMIDINE DERIVATIVES AS TAM INHIBITORS
    Publication number: 20200181151
    Abstract: This application relates to compounds of Formula I: or pharmaceutically acceptable salts thereof, which are inhibitors of TAM kinases which are useful for the treatment of disorders such as cancer.
    Type: Application
    Filed: November 15, 2019
    Publication date: June 11, 2020
    Inventors: Yun-Long Li, David M. Burns, Hao Feng, Joseph Glenn, Chunhong He, Taisheng Huang, Song Mei, Jun Pan, Xiaozhao Wang, Yingda Ye
  • PYRROLOTRIAZINE COMPOUNDS AS TAM INHIBITORS
    Publication number: 20200131185
    Abstract: This application relates to compounds of Formula I: or pharmaceutically acceptable salts thereof, which are inhibitors of TAM kinases which are useful for the treatment of disorders such as cancer.
    Type: Application
    Filed: September 4, 2019
    Publication date: April 30, 2020
    Inventors: Yun-Long Li, Xiaozhao Wang, Chunhong He
  • Substituted imidazo[1,2-a]pyrazines as LSD1 inhibitors
    Patent number: 10556908
    Abstract: The present invention is directed to imidazo[1,2-a]pyrazine derivatives of Formula I, or a pharmaceutically acceptable salt thereof, which are LSD1 inhibitors useful in the treatment of diseases such as cancer.
    Type: Grant
    Filed: September 13, 2018
    Date of Patent: February 11, 2020
    Assignee: Incyte Corporation
    Inventors: Liangxing Wu, Joel R. Courter, Chunhong He, Jingwei Li, Liang Lu, Yaping Sun, Xiaozhao Wang, Wenqing Yao, Colin Zhang, Jincong Zhuo
  • FUSED PYRAZINE DERIVATIVES AS A2A / A2B INHIBITORS
    Publication number: 20200031835
    Abstract: This application relates to compounds of Formula (I): or pharmaceutically acceptable salts thereof, which modulate the activity of adenosine receptors, such as subtypes A2A and A2B receptors, and are useful in the treatment of diseases related to the activity of adenosine receptors including, for example, cancer, inflammatory diseases, cardiovascular diseases, and neurodegenerative diseases.
    Type: Application
    Filed: July 3, 2019
    Publication date: January 30, 2020
    Inventors: Xiaozhao Wang, Peter Niels Carlsen, Pei Gan, Gia Hoang, Yong Li, Chao Qi, Liangxing Wu, Wenqing Yao, Zhiyong Yu, Wenyu Zhu
  • TRIAZOLOPYRIDINES AND TRIAZOLOPYRAZINES AS LSD1 INHIBITORS
    Publication number: 20200024277
    Abstract: The present invention is directed to [1,2,4]triazolo[1,5-a]pyridine and [1,2,4]triazolo[1,5-a]pyrazine derivatives which are LSD1 inhibitors useful in the treatment of diseases such as cancer.
    Type: Application
    Filed: October 3, 2019
    Publication date: January 23, 2020
    Inventors: Liangxing Wu, Xiaozhao Wang, Wenqing Yao, Colin Zhang
  • Pyrrolopyrimidine derivatives as TAM inhibitors
    Patent number: 10519163
    Abstract: This application relates to compounds of Formula I: or pharmaceutically acceptable salts thereof, which are inhibitors of TAM kinases which are useful for the treatment of disorders such as cancer.
    Type: Grant
    Filed: July 11, 2018
    Date of Patent: December 31, 2019
    Assignee: Incyte Corporation
    Inventors: Yun-Long Li, David M. Burns, Hao Feng, Joseph Glenn, Chunhong He, Song Mei, Jun Pan, Xiaozhao Wang, Yingda Ye
  • FUSED PYRIMIDINE DERIVATIVES AS A2A / A2B INHIBITORS
    Publication number: 20190375752
    Abstract: This application relates to compounds of Formula (I): or pharmaceutically acceptable salts thereof, which modulate the activity of adenosine receptors, such as subtypes A2A and A2B receptors, and are useful in the treatment of diseases related to the activity of adenosine receptors including, for example, cancer, inflammatory diseases, cardiovascular diseases, and neurodegenerative diseases.
    Type: Application
    Filed: May 17, 2019
    Publication date: December 12, 2019
    Inventors: Xiaozhao Wang, Heeoon Han, Matthew S. McCammant, Liangxing Wu, Wenqing Yao, Zhiyong Yu, Le Zhao
  • PYRROLE TRICYCLIC COMPOUNDS AS A2A / A2B INHIBITORS
    Publication number: 20190337957
    Abstract: This application relates to compounds of Formula (I): or pharmaceutically acceptable salts or stereoisomers thereof, which modulate the activity of adenosine receptors, such as subtypes A2A and A2B receptors, and are useful in the treatment of diseases related to the activity of adenosine receptors including, for example, cancer, inflammatory diseases, cardiovascular diseases, and neurodegenerative diseases.
    Type: Application
    Filed: April 8, 2019
    Publication date: November 7, 2019
    Inventors: Xiaozhao Wang, Peter Niels Carlsen, Chunhong He, Taisheng Huang
  • Pyrrolotriazine compounds as TAM inhibitors
    Patent number: 10442810
    Abstract: This application relates to compounds of Formula I: or pharmaceutically acceptable salts thereof, which are inhibitors of TAM kinases which are useful for the treatment of disorders such as cancer.
    Type: Grant
    Filed: May 4, 2018
    Date of Patent: October 15, 2019
    Assignee: Incyte Corporation
    Inventors: Yun-Long Li, Xiaozhao Wang, Chunhong He
  • IMIDAZOPYRIMIDINES AND TRIAZOLOPYRIMIDINES AS A2A / A2B INHIBITORS
    Publication number: 20190292188
    Abstract: This application relates to compounds of Formula (I): or pharmaceutically acceptable salts or stereoisomers thereof, which modulate the activity of adenosine receptors, such as subtypes A2A and A2B receptors, and are useful in the treatment of diseases related to the activity of adenosine receptors including, for example, cancer, inflammatory diseases, cardiovascular diseases, and neurodegenerative diseases.
    Type: Application
    Filed: February 26, 2019
    Publication date: September 26, 2019
    Inventors: Xiaozhao Wang, Pei Gan, Heeoon Han, Taisheng Huang, Matthew S. McCammant, Chao Qi, Ding-Quan Qian, Liangxing Wu, Wenqing Yao, Zhiyong Yu, Fenglei Zhang
  • BICYCLIC HETEROCYCLES AS FGFR4 INHIBITORS
    Publication number: 20190269693
    Abstract: The present disclosure relates to bicyclic heterocycles of Formula (I?), and pharmaceutical compositions of the same, that are inhibitors of the FGFR3 and/or FGFR4 enzyme and are useful in the treatment of FGFR-associated diseases.
    Type: Application
    Filed: February 15, 2019
    Publication date: September 5, 2019
    Inventors: Liang Lu, Bo Shen, Alexander Sokolsky, Xiaozhao Wang, Liangxing Wu, Wenqing Yao, Yingda Ye
  • CYCLOPROPYLAMINES AS LSD1 INHIBITORS
    Publication number: 20190211014
    Abstract: The present invention is directed to cyclopropylamine derivatives which are LSD1 inhibitors useful in the treatment of diseases such as cancer.
    Type: Application
    Filed: November 19, 2018
    Publication date: July 11, 2019
    Inventors: Liangxing Wu, Joel R. Courter, Chunhong He, Ding-Quan Qian, Bo Shen, Xiaozhao Wang, Wenqing Yao, Fenglei Zhang
  • Cyclopropylamines as LSD1 inhibitors
    Patent number: 10300051
    Abstract: The present invention is directed to cyclopropylamine derivatives which are LSD1 inhibitors useful in the treatment of diseases such as cancer.
    Type: Grant
    Filed: October 5, 2016
    Date of Patent: May 28, 2019
    Assignee: Incyte Corporation
    Inventors: Liangxing Wu, Joel R. Courter, Chunhong He, Bo Shen, Xiaozhao Wang, Wenqing Yao, Fenglei Zhang